The FDA Endocrinologic and Metabolic Drugs Advisory Committee did not recommend approval of Sanofi-Aventis’ rimonabant (Zimulti / Acomplia) to the FDA for use in obese and overweight patients with associated risks factors. The company will continue to work closely with the FDA regarding the committee’s recommendations. The FDA will take action by July 26, 2007 for rimonabant. Rimonabant is the first member of a new therapeutic class of drugs that selectively block the CB1 recep...